Y. Iwakura, H. Ishigame, S. Saijo, and S. Nakae, Functional Specialization of Interleukin-17 Family Members, Immunity, vol.34, issue.2, pp.149-62
DOI : 10.1016/j.immuni.2011.02.012

S. L. Gaffen, Structure and signalling in the IL-17 receptor family, Nature Reviews Immunology, vol.452, issue.8, pp.556-67, 2009.
DOI : 10.4049/jimmunol.167.2.1004

D. J. Cua and C. M. Tato, Innate IL-17-producing cells: the sentinels of the immune system, Nature Reviews Immunology, vol.31, issue.7, pp.479-89
DOI : 10.4049/jimmunol.169.1.443

C. L. Roark, P. L. Simonian, A. P. Fontenot, W. K. Born, and R. L. O-'brien, ???? T cells: an important source of IL-17, Current Opinion in Immunology, vol.20, issue.3, pp.353-360, 2008.
DOI : 10.1016/j.coi.2008.03.006

R. M. Onishi and S. L. Gaffen, Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease, Immunology, vol.182, issue.3, pp.311-332, 2010.
DOI : 10.4049/jimmunol.179.6.4135

W. Ouyang, J. K. Kolls, and Y. Zheng, The Biological Functions of T Helper 17 Cell Effector Cytokines in Inflammation, Immunity, vol.28, issue.4, pp.454-467, 2008.
DOI : 10.1016/j.immuni.2008.03.004

B. Yang, The Role of Interleukin 17 in Tumour Proliferation, Angiogenesis, and Metastasis, Mediators of Inflammation, vol.31, issue.1, article 795, pp.10-1155, 2014.
DOI : 10.1016/j.leukres.2013.06.022

X. Zhu, IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines, Breast Cancer Research, vol.67, issue.6, pp.10-1186, 2008.
DOI : 10.1159/000028045

W. C. Chen, Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor, Histopathology, vol.42, issue.2, pp.225-258, 2013.
DOI : 10.1002/eji.201242740

M. Numasaki, Interleukin-17 promotes angiogenesis and tumor growth, Blood, vol.101, issue.7, pp.2620-2627, 2003.
DOI : 10.1182/blood-2002-05-1461

J. S. Nam, Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17, Cancer Res, vol.10, pp.3915-3938, 2008.

S. Cochaud, IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2. Sci Rep. 3, 3456; doi: 10, p.3456, 1038.

J. Bastid, N. Bonnefoy, J. F. Eliaou, and A. Bensussan, Lymphocyte-derived interleukin-17A adds another brick in the wall of inflammation-induced breast carcinogenesis, OncoImmunology, vol.3, issue.4, p.28273, 2014.
DOI : 10.1126/scitranslmed.3001374

URL : https://hal.archives-ouvertes.fr/hal-02110853

C. K. Huang, Autocrine/paracrine mechanism of interleukin-17B receptor promotes breast tumorigenesis through NF-??B-mediated antiapoptotic pathway, Oncogene, vol.9, issue.23, pp.2968-77, 2014.
DOI : 10.1016/S1046-2023(03)00032-X

S. Furuta, IL-25 Causes Apoptosis of IL-25R-Expressing Breast Cancer Cells Without Toxicity to Nonmalignant Cells, Science Translational Medicine, vol.357, issue.1, pp.78-3116, 2011.
DOI : 10.1056/NEJMra043186

A. J. King, The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338, Nature, vol.270, issue.6707, pp.180-183, 1998.
DOI : 10.1074/jbc.270.39.22731

C. S. Mason, Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO, pp.2137-2185, 1999.

, Gene and GenBank accession Primer sequence Product length IL17-A # NM_002190.2 5'-ACTACAACCGATCCACCTCAC-3' 83 bp 5

I. Nm_022789, 3 5'-TCCCCCTGGAGATATGAGTTGGACA-3' 175 bp 5



I. , 3 5'-GGCTTGGTTTCACGCGCAGC-3' 192 bp 5


, ? -Actin 5'-CAGCCATGTACGTTGCTATCCAGG-3' 151 bp 5

S. E. Ghayad and P. A. Cohen, Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients, Recent Patents on Anti-Cancer Drug Discovery, vol.5, issue.1, pp.29-57, 2010.
DOI : 10.2174/157489210789702208

N. Pullen and G. Thomas, FEBS Letters, vol.267, issue.1, pp.78-82, 1997.
DOI : 10.1016/S0092-8674(00)81257-X

Q. P. Weng, Journal of Biological Chemistry, vol.264, issue.26, pp.16621-16630, 1998.
DOI : 10.1016/0092-8674(92)90643-Q

D. C. Porter and K. Keyomarsi, Novel splice variants of cyclin E with altered substrate specificity, Nucleic Acids Research, vol.28, issue.23, p.101, 2000.
DOI : 10.1093/nar/28.23.e101

H. Wingate, The Tumor-specific Hyperactive Forms of Cyclin E Are Resistant to Inhibition by p21 and p27, Journal of Biological Chemistry, vol.277, issue.15, pp.15148-57, 2005.
DOI : 10.1002/1097-0142(20001201)89:11<2247::AID-CNCR13>3.0.CO;2-5

X. D. Wang, J. L. Rosales, A. Magliocco, R. Gnanakumar, and K. Lee, Cyclin E in breast tumors is cleaved into its low molecular weight forms by calpain, Oncogene, vol.22, issue.5, pp.769-74, 2003.
DOI : 10.1023/A:1006102916060

A. S. Chung, An interleukin-17???mediated paracrine network promotes tumor resistance to anti-angiogenic therapy, Nature Medicine, vol.59, issue.9, pp.1114-1137, 2013.
DOI : 10.1177/002215540305100503

V. Younesi and F. Nejatollahi, Induction of anti-proliferative and apoptotic effects by anti-IL-25 receptor single chain antibodies in breast cancer cells, International Immunopharmacology, vol.23, issue.2, pp.624-656, 2015.
DOI : 10.1016/j.intimp.2014.10.015

M. T. Duong, LMW-E/CDK2 Deregulates Acinar Morphogenesis, Induces Tumorigenesis, and Associates with the Activated b-Raf-ERK1/2-mTOR Pathway in Breast Cancer Patients, PLoS Genetics, vol.34, issue.3, 2012.
DOI : 10.1371/journal.pgen.1002538.s012

C. K. Weber, J. R. Slupsky, H. A. Kalmes, and U. R. Rapp, Active Ras induces heterodimerization of cRaf and BRaf, Cancer Res, vol.61, pp.3595-3603, 2001.

L. K. Rushworth, A. D. Hindley, E. O-'neill, and W. Kolch, Regulation and Role of Raf-1/B-Raf Heterodimerization, Molecular and Cellular Biology, vol.26, issue.6, pp.2262-72
DOI : 10.1128/MCB.26.6.2262-2272.2006

T. Benatar, IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo, Cancer Immunology, Immunotherapy, vol.116, issue.6, pp.805-822, 2010.
DOI : 10.4049/jimmunol.176.2.1013

Y. Chin, Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer, Anticancer Res, vol.12, pp.1463-1469, 1992.

M. Schmidt, The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer, Cancer Research, vol.68, issue.13, pp.5405-5418, 2008.
DOI : 10.1158/0008-5472.CAN-07-5206

J. S. Jung, Association of IL-17RB Gene Polymorphism With Asthma, Chest, vol.135, issue.5, pp.1173-80, 2009.
DOI : 10.1378/chest.08-1595

M. Hagn, Human B Cells Secrete Granzyme B When Recognizing Viral Antigens in the Context of the Acute Phase Cytokine IL-21, The Journal of Immunology, vol.183, issue.3, pp.1838-1883, 2009.
DOI : 10.4049/jimmunol.0901066

O. Wiedow, J. M. Schroder, H. Gregory, J. A. Young, and E. Christophers, Elafin, J Biol Chem, vol.32, pp.14791-14796, 1990.
DOI : 10.1021/bi00058a021

M. Zhang, Z. Zou, N. Maass, and R. Sager, Differential expression of elafin in human normal mammary epithelial cells and carcinomas is regulated at the transcriptional level, Cancer Res, vol.55, pp.2537-2578, 1995.

M. Sarra, IL-25 prevents and cures fulminant hepatitis in mice through a myeloid-derived suppressor cell-dependent mechanism, Hepatology, vol.18, issue.4, pp.1436-50
DOI : 10.1038/nm.2735

URL : http://onlinelibrary.wiley.com/doi/10.1002/hep.26446/pdf

V. Dolgachev, B. C. Petersen, A. L. Budelsky, A. A. Berlin, and N. W. Lukacs, Pulmonary IL-17E (IL-25) Production and IL-17RB+ Myeloid Cell-Derived Th2 Cytokine Production Are Dependent upon Stem Cell Factor-Induced Responses during Chronic Allergic Pulmonary Disease, The Journal of Immunology, vol.183, issue.9, pp.5705-5720, 2009.
DOI : 10.4049/jimmunol.0901666

URL : http://www.jimmunol.org/content/jimmunol/183/9/5705.full.pdf

T. Miyagaki, IL-22, but Not IL-17, Dominant Environment in Cutaneous T-cell Lymphoma, Clinical Cancer Research, vol.17, issue.24, pp.7529-7567
DOI : 10.1158/1078-0432.CCR-11-1192

URL : http://clincancerres.aacrjournals.org/content/clincanres/17/24/7529.full.pdf

C. Mayer, DNA repair capacity after ??-irradiation and expression profiles of DNA repair genes in resting and proliferating human peripheral blood lymphocytes, DNA Repair, vol.1, issue.3, pp.237-50, 2002.
DOI : 10.1016/S1568-7864(01)00019-2